Abstract: An object of the present invention is to provide a method of assisting diagnosis of inflammatory bowel disease, which can specifically determine inflammatory bowel disease. The present invention relates to “a method of assisting diagnosis of inflammatory bowel disease, the method including subjecting a subject-derived specimen to a reduction treatment and subsequently measuring a human prohaptoglobin amount in the specimen by using an antibody 1 which is an antibody that specifically binds to an amino acid sequence set forth in SEQ ID NO: 1, and determining that a subject has inflammatory bowel disease by using the human prohaptoglobin amount as an indicator, and relates to an examination kit for assisting diagnosis of inflammatory bowel disease, including the antibody 1 a reducing agent”.

Abstract: The invention provides gastroenterological cancer determination methods that involve contacting a specimen, an antibody 1 that recognizes an ? chain of human haptoglobin, and an antibody 2 that recognizes a ? chain of human haptoglobin and does not recognize human haptoglobin in which an S—S bond is cleaved to form a complex 1, or contacting the specimen and two antibodies selected from the antibodies 2 that recognize a ? chain of human haptoglobin and do not recognize human haptoglobin in which an S—S bond is cleaved to form a complex 2. A determination is made based on the measurement of complex 1 or 2. Alternatively, the specimen and two antibodies selected from the antibodies 1 that recognize an ? chain of human haptoglobin are contacted to form a complex 3, and a determination is made by comparing the measurement results of complex 1 or 2 with complex 3.

Abstract: [Problem] To provide a method for detecting high-risk prostate cancer, for the purpose of providing useful information, such as necessity of biopsy, to a test-positive patient in a PSA test. [Solution] The method for detecting high-risk prostate cancer according to the present invention comprises reacting a PSA contained in a sample composed of urine collected from a human body which is suspected to be suffering from prostate cancer with (1) a fucose ?1?6 affinitive lectin which has a characteristic property that the lectin has affinity expressed by a binding constant of 1.0×104 M?1 or more (at 25° C.) for an ?1?6 fucose sugar chain No. 405. The fucose ?1?6 affinitive lectin is preferably (2) a fucose ?1?6 specific lectin which has a characteristic property that the lectin has a binding constant of 1.0×104 M?1 or less (at 25° C.) for a sugar chain No. 003 that does not contain ?1?6 fucose and a glycolipid-type sugar chain No. 909 that does not contain ?1?6 fucose.

Abstract: The invention provides gastroenterological cancer determination methods that involve contacting a specimen, an antibody 1 that recognizes an ? chain of human haptoglobin, and an antibody 2 that recognizes a ? chain of human haptoglobin and does not recognize human haptoglobin in which an S—S bond is cleaved to form a complex 1, or contacting the specimen and two antibodies selected from the antibodies 2 that recognize a ? chain of human haptoglobin and do not recognize human haptoglobin in which an S—S bond is cleaved to form a complex 2. A determination is made based on the measurement of complex 1 or 2. Alternatively, the specimen and two antibodies selected from the antibodies 1 that recognize an ? chain of human haptoglobin are contacted to form a complex 3, and a determination is made by comparing the measurement results of complex 1 or 2 with complex 3.

Abstract: [Problem] To provide a method for detecting prostate cancer, the method having a higher degree of certainty than the PSA blood test and providing measurement values that correlate with risk classification. [Solution] This method for detecting prostate cancer is characterized in that: the method includes reacting fucose ?1?6 specific lectin and fucosylated PSA contained in a sample constituted of serum collected from a subject, and detecting the reacted lectin; and the pH in at least one step of the group consisting of the reaction step for reacting the fucosylated PSA and the lectin and processing steps thereafter is adjusted to above 8.5 and less than 11.0.

Abstract: [Problem] To provide a method for detecting high-risk prostate cancer, for the purpose of providing useful information, such as necessity of biopsy, to a test-positive patient in a PSA test. [Solution] The method for detecting high-risk prostate cancer according to the present invention comprises reacting a PSA contained in a sample composed of urine collected from a human body which is suspected to be suffering from prostate cancer with (1) a fucose ?1?6 affinitive lectin which has a characteristic property that the lectin has affinity expressed by a binding constant of 1.0×104 M?1 or more (at 25° C.) for an ?1?6 fucose sugar chain No. 405. The fucose ?1?6 affinitive lectin is preferably (2) a fucose ?1?6 specific lectin which has a characteristic property that the lectin has a binding constant of 1.0×104 M?1 or less (at 25° C.) for a sugar chain No. 003 that does not contain ?1?6 fucose and a glycolipid-type sugar chain No. 909 that does not contain ?1?6 fucose.

Abstract: The instant invention provides a method for the differential diagnosis of inflammatory bowel disease which comprises, determining the relative ratio of G0 oligosaccharide represented by formula (I): to G2 oligosaccharide represented by formula (II): wherein G represents galactose, M represents mannose, GN represents N-acetylglucosamine and F represents fucose in serum IgG oligosaccharide fraction obtained from a patient with inflammatory bowel disease or a patient with suspicion of inflammatory bowel disease, and discriminating inflammatory bowel disease based on the obtained ratio.

Abstract: The determination (test, diagnosis) of pancreatic cancer can be performed with high accuracy by detecting a fucosylated sugar chain (N-glycan) present in a specific site of the human haptoglobin and using an amount of the fucosylated sugar chain as a tumor marker for pancreatic cancer.

Abstract: The present invention provides a peptide or protein having a neovascularization action and containing a basic amino acid cluster region of ?1,6-N-acetylglucosaminyltransferase, a neovascularization accelerator containing the above-mentioned peptide or protein, a method of screening an inhibition substance for the above-mentioned peptide or protein, and a neovascularization inhibitor containing this inhibition substance.

Abstract: The instant invention provides a method for the differential diagnosis of inflammatory bowel disease which comprises, determining the relative ratio of G0 oligosaccharide represented by formula (I): to G2 oligosaccharide represented by formula (II): wherein G represents galactose, M represents mannose, GN represents N-acetylglucosamine and F represents fucose in serum IgG oligosaccharide fraction obtained from a patient with inflammatory bowel disease or a patient with suspicion of inflammatory bowel disease, and discriminating inflammatory bowel disease based on the obtained ratio.

Abstract: The determination (test, diagnosis) of pancreatic cancer can be performed with high accuracy by detecting a fucosylated sugar chain (N-glycan) present in a specific site of the human haptoglobin and using an amount of the fucosylated sugar chain as a tumor marker for pancreatic cancer.

Abstract: The present invention relates to a method for identifying a pluripotent hepatic progenitor cell, a method for separating the pluripotent hepatic progenitor cell and a method for producing the pluripotent hepatic progenitor cell.

Abstract: The present invention provides a peptide or protein having a neovascularization action and containing a basic amino acid cluster region of ?1,6-N-acetylglucosaminyltransferase, a neovascularization accelerator containing the above-mentioned peptide or protein, a method of screening an inhibition substance for the above-mentioned peptide or protein, and a neovascularization inhibitor containing this inhibition substance.

Abstract: The present invention relates to a method for identifying a pluripotent hepatic progenitor cell, a method for separating the pluripotent hepatic progenitor cell and a method for producing the pluripotent hepatic progenitor cell.

Abstract: A pharmaceutical agent which inhibits a replication of virus by increasing the specific enzymatic activity of liver and/or other tissue is offered.A viral replication inhibitor which contains N-acetyl-glucosaminyltransferase III (GnT-III) or gene thereof as an effective component. Examples of the gene are that which contains a sequence represented by SEQ ID NO:1 (length: 1,608) or by SEQ ID NO:2 (length: 1,593) in the Sequence List, that which is prepared by hybridization of it and codes for a polypeptide having a GnT-III activity or a functionally same activity and that in which the above is further integrated in vector.

Abstract: A mounting device of a lithoplate, having a head clamp and a tail clamp of a lithoplate provided at a cutout portion of a plate cylinder, includes a register pin fixed to a lower blade of the head such that it penetrates through and projects from an upper blade of the head clamp. A clamp provided to the mounting device of a lithoplate includes a clamp having a register pin at an upper surface of an upper blade of the clamp and a roller which can freely rotate is provided at the position of a plate cylinder side opposed to the register pin. The mounting device of a lithoplate also includes a device for covering at least a part of a lithoplate holding tail edge at a region between a tip of a vise at a tail side and a plate cylinder to which no pressure is applied.

Abstract: An isolated DNA having a promoter activity in an animal cell; a method for expressing a useful gene using the isolated DNA; and a method for producing a protein in an animal cell using the isolated DNA. The present invention provides a method for producing a desired gene product in a large quantity in an animal cell.

Abstract: A stud welding method uses an inert mixed gas as arc shield in performing stud welding on a base metal, such as, vehicle body, by utilizing the stud, e.g. a T-stud, as an electrode, the stud serving as the positive pole while the base metal serves as the negative pole to thereby prevent formation of oxide film on the base metal surface during the welding, the inert mixed gas comprising carbon dioxide gas and argon gas.

Abstract: Strong and tough steel is prepared by heating to a temperature of 800.degree. - 1000.degree. C., preferably from 800.degree. to 950.degree. C., before the rolling step, finish rolling at temperatures within the range of from 680.degree. to 850.degree. C., preferably from 680.degree. to 800.degree. C. and with a reduction ratio in thickness of not less than 30% based on the plate thickness of the steel when the finish rolling is started. It is advantageous to provide for a pretreatment of the steel, said pretreatment including the steps of initially heating the steel to a temperature higher than 1000.degree. C., rolling the heated steel to a suitable intermediate thickness and cooling the rolled steel to a temperature lower than 650.degree. C.Tempering may also be carried out at a temperature of 500.degree. - 650.degree. C. for 20 minutes -- 2 hours.